Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials.

European heart journal2024PMID: 38416593

View on PubMed DOI: 10.1093/eurheartj/ehae028

Authors

Mellbin, Linda G; Bhatt, Deepak L; David, Jens-Peter; Ekström, Kathrine; Petrie, Mark C; Rasmussen, Søren; Vilsbøll, Tina

Keywords

Post hoc analysisCardiovascular outcomes trialGlucagon-like peptide-1 receptor agonistHbA1cMajor adverse cardiovascular eventsPIONEER 6SUSTAIN 6SemaglutideType 2 diabetes